Freeze-drying protective agent, freeze-drying nucleic acid reaction reagent and freeze-drying method thereof

By using lyophilized protective agents composed of trehalose and other lyophilized programs, the problems of long preparation time, poor performance consistency and high operating environment requirements in lyophilized technology are solved, and stable lyophilized and high-temperature preservation of DNA/RNA are achieved. Performance, simplifies operational steps and reduces shipping costs.

CN119020460APending Publication Date: 2024-11-26SHENZHEN DEXIA DIAGNOSTIC TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411285731.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing lyophilization technology has problems such as long preparation time for lyophilization, poor performance consistency, high operating environment requirements, inability to compatible DNA and RNA lyophilization, the need for multiple protective agents and different lyophilization procedures, and the short storage period of lyophilization after lyophilization. .

Method used

Using lyophilized protective agents composed of trehalose, hydroxypropyl-β-cyclodextrin, dextran and glycine, combined with specific lyophilized procedures, a lyophilized nucleic acid reaction reagent is formed to achieve universal lyophilized DNA/RNA and simplify operations. Steps and reduce shipping costs.

Benefits of technology

It realizes stable and reliable lyophilization of nucleic acid reaction reagents, reduces transportation costs, simplifies operating steps, improves the stability and performance consistency of reagents, ensures that the activity of enzymes and nucleic acids is maintained during DNA/RNA lyophilization, and the small balls are lyophilized after lyophilization. Good storage performance under high temperature conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020460A_ABST
    Figure CN119020460A_ABST
Patent Text Reader

Abstract

The invention discloses a freeze-drying protective agent, a freeze-drying nucleic acid reaction reagent and a freeze-drying method thereof, and the freeze-drying protective agent comprises 3-12 (w / v)% of trehalose, 2-8 (w / v)% of hydroxypropyl-beta-cyclodextrin, 0.5-5 (w / v)% of dextran-40, 4-12 mg / mL of glycine, 0.1-0.7 (wt)% of a bacteriostatic agent and the balance of water. The nucleic acid reaction reagent freeze-drying device can realize freeze-drying of nucleic acid reaction reagents, is convenient to transport and operate, is stable and reliable, can be stored and transported at normal temperature, reduces the transportation cost, reduces the operation steps, and improves the stability and reliability of the reagents. The freeze-drying protective agent not only can protect the freeze-drying process of the PCR reaction reagent, but also has simple components, and does not influence the amplification reaction and fluorescence value of fluorescent PCR. In addition, the freeze-drying protective agent and the freeze-drying method can realize universal freeze-drying of DNA / RNA reaction reagents, and freeze-drying of different reagents can be realized by using one protective agent and the freeze-drying method.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a freeze-drying protective agent, a freeze-dried nucleic acid reaction reagent and a freeze-drying method thereof. Background Art

[0002] In 1992, Japanese scientist Higuchi first introduced the fluorescent dye ethidium bromide (EB) into the PCR system to monitor changes in nucleic acid content in real time, thus developing real-time fluorescence quantitative PCR (qPCR) technology. By directly reading the signal, this method avoids the steps of traditional open-cap product detection and effectively solves the problems of complex operation and nucleic acid cross-contamination in traditional PCR technology. In addition, the linear relationship between the cycle threshold (Ct value) of the template and the starting copy number during the PCR process makes nucleic acid quantification a reality. Real-time fluorescence quantitative PCR technology has been widely used in many fields in recent years due to its rapid, specific and sensitive characteristics, including food safety testing, pathogen identification and oncogene diagnosis.

[0003] Traditional liquid PCR reagents need to be stored, prepared and transported in a low-temperature environment. Each time the reagent is prepared, it needs to be thawed, and repeated freezing and thawing will reduce the stability of the product. Liquid reagents usually need to be transported at -20°C, which not only increases transportation costs, but also increases the complexity of operation. In addition, the use of reagents has high requirements on the quality and environment of operators. In order to solve the above problems, it is necessary to find a method to store qPCR reagents in a "premixed" form and ensure that their original activity is not affected. In this case, freeze-drying technology becomes an ideal choice. Before freeze-drying, the reagents are pre-mixed and accurately dispensed into each usage amount. After removing the water, the activity of the reagents under the original storage conditions is maintained, and the activity can be maintained even at room temperature. In addition, when using it, the operator only needs to simply add water to reconstitute it, without the need for special instruments, which reduces the requirements for personnel skills and equipment.

[0004] Freeze-drying technology has many advantages, which makes it widely used in the field of biological preparations. First of all, biological preparations in a freeze-dried state can be stored and transported at room temperature, which not only helps to maintain its biological activity, but also reduces transportation costs, and is particularly suitable for long-distance transportation. In addition, by using suitable freeze-drying protectants, enzymes and proteins can be effectively protected to avoid loss of activity during the freeze-drying process, thereby extending the shelf life of the product and reducing the activity of bacteria and enzymes. At the same time, this technology simplifies the operation steps and is convenient for clinical personnel to use. However, freeze-drying technology also has some disadvantages, such as challenges such as long freeze-drying preparation time, poor performance consistency, and high operating environment requirements. It is impossible to make a protective agent compatible with DNA and RNA freeze-drying. It is necessary to develop multiple protective agents, and each reagent needs to use a different freeze-drying procedure, and different procedures need to be explored; in addition, the freeze-dried pellets have a storage period of too short at 45-50°C (special temperature for sea transportation in summer), and the performance of the pellets deteriorates rapidly in 2-5 days. Summary of the invention

[0005] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, the present invention aims to provide a lyophilization protectant, a lyophilized nucleic acid reaction reagent and a lyophilization method thereof.

[0006] To achieve the above object, according to the first aspect of the present invention, the freeze-drying protection agent provided by the present invention is used for the freeze-drying protection of DNA / RAN reaction reagents, characterized in that it includes trehalose 3-12 (w / v)%, hydroxypropyl-β-cyclodextrin 2-8 (w / v)%, dextran-40 0.5-5 (w / v)%, glycine 4-12 mg / mL, antibacterial agent 0.1-0.7 (wt)%, and the rest is water.

[0007] According to one embodiment of the present invention, the trehalose is 6-12 (w / v)%, hydroxypropyl-β-cyclodextrin is 3-5 (w / v)%, dextran-40 is 0.5-2 (w / v)%, glycine is 7-10 mg / mL, antibacterial agent is 0.1-0.4 (wt)%, and the balance is water.

[0008] According to a second aspect of the present invention, the freeze-dried nucleic acid reaction reagent provided by the present invention comprises:

[0009] PCR reaction reagents;

[0010] Lyoprotectants as described above.

[0011] According to one embodiment of the present invention, the PCR reaction reagents include a buffer, a surfactant, a glycerol-free enzyme, primers and a probe;

[0012] Wherein, the buffer is a buffer without glycerol, and the primers and probes are primers and probes purified by HPLC.

[0013] According to one embodiment of the present invention, the volume ratio of the lyophilized protectant to the PCR reaction reagent is 1:1.

[0014] According to a third aspect of the present invention, the present invention provides a freeze-drying method for a nucleic acid reaction reagent, comprising:

[0015] Mixing a lyophilized protective agent with a PCR reaction reagent to form a mixed solution; the lyophilized protective agent is the lyophilized protective agent according to claim 1 or 2;

[0016] The mixed solution is added into a liquid nitrogen container to condense and form microspheres;

[0017] The microspheres are transferred to a freeze dryer and freeze-dried according to a predetermined freeze-drying program to obtain finished freeze-dried reaction reagent microspheres.

[0018] According to one embodiment of the present invention, the predetermined freeze-drying program comprises:

[0019] Pre-freezing stage: maintain the temperature at 4°C for 1.5-2 hours, then lower the temperature to -40 to -50°C and maintain for 1-3 hours;

[0020] Sublimation drying stage: maintain vacuum degree of 8 to 15 Pa, first at -50 ° C for 8 hours; then adjust the temperature to -45 ° C for 4 hours; then adjust the temperature to -35 ° C for 6 hours; then adjust the temperature to -25 ° C for 4 hours; finally, adjust the temperature to -10 ° C for 4 hours;

[0021] Analysis and drying stage: maintain a vacuum degree of 8 to 15 Pa, first at a temperature of 5 ° C for 4 hours; then adjust the temperature to 25 ° C for 6 hours; finally adjust the temperature to 35 ° C for 4 hours.

[0022] Through the above technical scheme, the present invention can realize the freeze drying of nucleic acid reaction reagents, which is convenient to transport and operate, stable and reliable, and can realize storage and transportation at room temperature, reduce transportation costs and operation steps, and improve the stability and reliability of reagents. The freeze-drying protective agent can not only protect the freeze-drying process of PCR reaction reagents, but also the added protective agent has simple ingredients and does not affect the amplification reaction and fluorescence value of fluorescent PCR. In addition, the freeze-drying protective agent and freeze-drying method can realize the universal freeze drying of DNA / RNA reaction reagents, and freeze drying of different reagents can be achieved using a protective agent and freeze-drying method.

[0023] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1It is the result of three lyophilized reagents in 25 μL template volume;

[0025] Figure 2 It is the result of three lyophilized reagents in 5 μL template volume;

[0026] Figure 3 These are the appearance results of three different lyophilized reagents;

[0027] Figure 4 This is the appearance result of freeze-dried reagent 2. DETAILED DESCRIPTION

[0028] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. Preferred embodiments of the present invention are given below. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0030] The present invention has been accomplished based on the following findings and studies by the inventors.

[0031] Freeze-drying technology has many advantages, which makes it widely used in the field of biological preparations. First, freeze-dried biological preparations can be stored and transported at room temperature, which not only helps to maintain their biological activity, but also reduces transportation costs, and is particularly suitable for long-distance transportation. In addition, by using appropriate freeze-drying protectants, enzymes and proteins can be effectively protected to avoid loss of activity during the freeze-drying process, thereby extending the shelf life of the product and reducing the activity of bacteria and enzymes. At the same time, this technology simplifies the operating steps and is convenient for clinical personnel to use.

[0032] Freeze-drying technology also has some disadvantages, such as the long time required to prepare freeze-dried products, increased production cycle, and low production efficiency. In addition, the morphology and stability of freeze-dried products are affected by protective agents and excipients, which may lead to inconsistent performance. During the production and packaging process, the operating environment requirements are relatively high, and it needs to be carried out under low temperature and low humidity conditions to prevent the freeze-dried products from absorbing moisture and becoming ineffective. In addition, the technical complexity of the freeze-drying preparation process also means that professional equipment and technology are required, which places higher requirements on the company's initial investment and operating capabilities.

[0033] More specifically, the current freeze-drying technology has the following major problems: 1. The main problems currently faced by freeze-drying technology include challenges such as long freeze-drying preparation time, poor performance consistency and high operating environment requirements; 2. It is impossible to make one protective agent compatible with DNA and RNA freeze-drying, and multiple protective agents need to be developed; 3. Each reagent requires a different freeze-drying procedure, and different procedures need to be explored; 4. The storage period of the freeze-dried pellets at 45-50°C (special temperature for sea transportation in summer) is too short, and the performance of the pellets deteriorates rapidly in 2-5 days.

[0034] Based on the above problems, the embodiments of the present invention provide a lyophilization protectant, a lyophilized nucleic acid reaction reagent and a lyophilization method thereof.

[0035] The freeze-drying protective agent provided by the invention is used for freeze-drying protection of DNA / RAN reaction reagents, and comprises 3-12 (w / v)% of trehalose, 2-8 (w / v)% of hydroxypropyl-β-cyclodextrin, 0.5-5 (w / v)% of dextran-40, 4-12 mg / mL of glycine, 0.1-0.7 (wt)% of an antibacterial agent, and the remainder is water.

[0036] Among the above components, trehalose, as the main component of the lyoprotectant, is a non-reducing sugar composed of special disaccharide molecules, which is easily soluble in water, and its solubility in water changes significantly with temperature; trehalose has the highest glass transition temperature (115°C), which can effectively increase the glass transition temperature of nucleic acid reaction reagents. Trehalose also has low hygroscopic properties, so there is no need to worry about the glass transition temperature of nucleic acid reaction reagents being lowered due to its hygroscopic properties. Trehalose, as a stable non-reducing disaccharide, does not contain reducing groups, does not react with active substances such as proteins, and has a non-specific protective effect on biological macromolecules and organisms.

[0037] Hydroxypropyl-β-cyclodextrin and dextran-40 mainly play a supporting role in freeze-drying, that is, forming a skeleton structure. At the same time, hydroxypropyl-β-cyclodextrin can increase the solubility and stability after freeze-drying.

[0038] Dextran-40 refers to a homopolysaccharide composed of glucose as a monosaccharide, with glucose units connected by glycosidic bonds. Dextran has the function of increasing the glass transition temperature of the mixed solution of biological products, and also acts as a cryoprotectant and dehydration protectant.

[0039] Glycine is usually added as a bulking agent or buffer, and its stabilizing properties show synergy with sugars. The role of antibacterial agents is to prevent microbial contamination and degradation of freeze-dried products during long-term storage, thereby ensuring product stability and safety.

[0040] This lyophilization protectant uses a variety of active ingredients that are highly efficient and low-temperature resistant to freeze-drying stress, such as trehalose and dextran, to form a synergistic protection effect. It not only protects the structure of nucleic acid molecules, but also effectively maintains the activity of biological enzymes such as DNA / RNA enzymes. The ingredients cooperate with each other to provide skeleton support and increase solubility and stability. In addition, it contains antibacterial agents to ensure that the product is not contaminated by microorganisms after long-term storage.

[0041] Preferably, trehalose 6-12 (w / v)%, hydroxypropyl-β-cyclodextrin 3-5 (w / v)%, dextran-40 0.5-2 (w / v)%, glycine 7-10 mg / mL, antibacterial agent 0.1-0.4 (wt)%, and the balance is water. This preferred ratio range takes into account the interaction and performance conditions between the components, so that the entire protective agent can exert synergistic protective efficacy to a greater extent, while controlling possible adverse effects, thereby providing the most ideal freeze-drying protection environment for DNA / RNA reaction reagents.

[0042] The present invention also provides a freeze-dried nucleic acid reaction reagent, comprising a PCR reaction reagent and the freeze-dried protective agent as described in the above embodiment.

[0043] Preferably, the PCR reaction reagents include a buffer, a surfactant, a glycerol-free enzyme, and primers and probes; wherein the buffer is a glycerol-free buffer with a moderate or low ion concentration, such as a Tris buffer or a phosphate buffer. The glycerol-free buffer is conducive to improving the efficiency and specificity of the nucleic acid reaction, while also avoiding the adverse effects of glycerol on the stability of enzyme activity. Surfactants (such as Tween-20) can increase the permeability and mildness of the reaction solution, prevent the components of the reaction solution from being adsorbed on the tube wall and the surface of the device, thereby improving the reaction efficiency. The glycerol-free enzyme can effectively prevent nonspecific amplification from occurring, increase the specificity of the reaction and the purity of the product, and improve the reaction efficiency and sensitivity.

[0044] The primers and probes are HPLC purified primers and probes. That is, the primers and probes used are purified by HPLC purification technology to remove defects and mismatched sequences, thereby improving the specificity and specificity of the primers and probes, reducing non-specific binding and false positive results, and reducing the impact of salt ions in the primers and probes on subsequent freeze-drying.

[0045] Preferably, the volume ratio of the lyophilized protective agent to the PCR reaction reagent is 1:1.

[0046] The embodiment of the present invention also provides a freeze-drying method for a nucleic acid reaction reagent, comprising:

[0047] Mixing a lyophilized protective agent with a PCR reaction reagent to form a mixed solution; the lyophilized protective agent is the lyophilized protective agent according to claim 1 or 2;

[0048] The mixed solution is added into a liquid nitrogen container to condense and form microspheres;

[0049] The microspheres are transferred to a freeze dryer and freeze-dried according to a predetermined freeze-drying program to obtain finished freeze-dried reaction reagent microspheres.

[0050] In one embodiment of the present invention, the predetermined freeze-drying program comprises:

[0051] Pre-freezing stage: maintain the temperature at 4°C for 1.5-2 hours, then lower the temperature to -40 to -50°C and maintain for 1-3 hours;

[0052] Sublimation drying stage: maintain vacuum degree of 8 to 15 Pa, first at -50 ° C for 8 hours; then adjust the temperature to -45 ° C for 4 hours; then adjust the temperature to -35 ° C for 6 hours; then adjust the temperature to -25 ° C for 4 hours; finally, adjust the temperature to -10 ° C for 4 hours;

[0053] Analysis and drying stage: maintain a vacuum degree of 8 to 15 Pa, first at a temperature of 5 ° C for 4 hours; then adjust the temperature to 25 ° C for 6 hours; finally adjust the temperature to 35 ° C for 4 hours.

[0054] Through the above technical scheme, the present invention can realize the freeze drying of nucleic acid reaction reagents, which is convenient to transport and operate, stable and reliable, and can realize storage and transportation at room temperature, reduce transportation costs and operation steps, and improve the stability and reliability of reagents. The freeze-drying protective agent can not only protect the freeze-drying process of the reaction reagents, but also the added protective agent has a simple composition and does not affect the amplification reaction and fluorescence value of fluorescent PCR. In addition, the freeze-drying protective agent and freeze-drying method can realize the universal freeze drying of DNA / RNA reaction reagents, and the freeze drying of different reagents can be achieved using a protective agent and freeze-drying method.

[0055] The present invention will be further described below through some specific embodiments.

[0056] Example 1 Configuration of freeze-dried nucleic acid reaction reagents

[0057] 1) First prepare the lyophilization protective agent according to the formula in Table 1, and then prepare the nucleic acid reaction reagent according to Table 2.

[0058] Table 1 Lyoprotectants

[0059]

[0060] After mixing according to the ratio in Table 1, store at room temperature for a short time or store in a refrigerator at 4 degrees for a long time. Prepare nucleic acid reaction reagents according to Table 2 (mix PCR reaction reagents and freeze-dried protective agents), that is, three nucleic acid reaction reagents are prepared by mixing Formula 1, Formula 2, and Formula 3 with PCR reaction reagents respectively.

[0061] Table 2 Preparation of 25 μL fluorescent PCR freeze-dried nucleic acid reaction reagent

[0062]

[0063] 2) Lyophilization of nucleic acid reaction reagents

[0064] Freeze-drying of nucleic acid reaction reagents. Pour liquid nitrogen into a sterilized iron container with a height of 5 cm and a liquid nitrogen addition amount of about 3 cm. After the liquid nitrogen stops boiling, use scissors to cut off 50 μl of the tip of the gun tip to prevent residue when dripping, and test whether there will be a lot of residue after the freeze-dried reagent is dripped out). Drop the prepared mixed solution (mixed solution of PCR reaction reagent and freeze-dried protective agent) into liquid nitrogen in a volume of 15 μl, condense into round balls (microspheres), wait for about 5-10 seconds, the balls sink to the bottom of the liquid nitrogen, and continue to drip one. After dripping, transfer to a vial or other iron container that has been pre-cooled with dry ice. Before transferring to the freeze dryer, some liquid nitrogen remains in the vial or iron container.

[0065] 3) Place in freeze dryer for freeze drying (Sihuan Freeze Dryer)

[0066] Table 3 Freeze-drying procedure

[0067]

[0068] Open the acrylic glove box in advance to let in dry air, and turn on the dehumidifier in the room for more than 1 hour, and then perform freeze-drying according to the above freeze-drying procedure. After freeze-drying, transfer the freeze-dried microspheres to the acrylic glove box for subpackaging or cover the vial cap.

[0069] 4) After freeze-drying, the performance of different freeze-drying protectants was evaluated

[0070] The three nucleic acid reaction reagents were freeze-dried to obtain three freeze-dried reagents. The performance of three different freeze-dried protective agents was evaluated. The extraction reagent used the nucleic acid release agent kit produced by Shenzhen Dexia Biomedical Engineering Co., Ltd. The detection kit used the new coronavirus nucleic acid detection kit produced by Shenzhen Dexia Biomedical Engineering Co., Ltd. The sample was mixed with the negative oral sample in proportion using the reference product purchased from Guangzhou Bondeson Biotechnology Co., Ltd.

[0071] The extraction process is as follows: insert the oral swab sample directly into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, shake the release agent 15 times manually, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification. After the extraction is completed, configure the reaction reagent according to Table 4.

[0072] Table 4 Lyophilized microsphere PCR reaction reagent configuration

[0073]

[0074] The amplification program is shown in Table 5:

[0075] Table 5 Amplification procedures

[0076]

[0077] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added, the lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed. The specific results are shown in Table 6 and Figure 1 and Figure 2 .

[0078] From the analysis of the appearance results, the freeze-dried appearance of the three freeze-dried reagents all meet the requirements (see Figure 3 ).

[0079] From the analysis of the amplification test results and CT value analysis, the freeze-dried reagent 3 has the best effect. When the template amount is the same, it is consistent with the liquid reagent. However, the freeze-dried reagent can use a template amount of 25μL, while the liquid reagent cannot use a template amount of 25μL. In terms of the sample amount of 5μL, the freeze-dried reagent 3 also has the best performance among the freeze-dried reagents 1, 2 and 3.

[0080] From the analysis of the fluorescence value of the amplified detection, whether it is 5 μL or 25 μL, the fluorescence value of the freeze-dried reagent 2 is the highest, and the subsequent examples will use the formula of the freeze-dried reagent 2 for verification.

[0081] Table 6 Results of different lyophilized reagents

[0082] 5 μL template 25 μL template Lyophilized reagent 1 21.1 18.4 Lyophilized reagent 2 21.19 18.4 Lyophilized reagent 3 20.44 18.15 Liquid contrast reagents 20.48 /

[0083] Example 2 Performance Evaluation of Freeze-Dried Reagent 2

[0084] 1) Prepare freeze-dried reagent 2 according to the formula in Table 7

[0085] Table 7 Freeze-dried reagent 2 configuration table

[0086]

[0087]

[0088] 2) Reagent freeze-drying

[0089] The specific freeze-drying process refers to the freeze-drying process in Example 1. Place in a freeze dryer for freeze drying (Sihuan Furui freeze dryer), and perform freeze drying according to the freeze drying program in Table 3. Open the acrylic glove box in advance to pass dry air, and turn on the dehumidifier in the room for more than 1H. After the freeze drying is completed, the freeze-dried beads are transferred to the acrylic glove box for subpackaging or covered with the vial cap.

[0090] 3) After freeze drying, the performance of freeze-dried protective agent 2 is evaluated

[0091] 3.1 Inspection of the appearance of freeze-dried reagent 2

[0092] The surface of the freeze-dried microspheres is intact and the appearance of the freeze-dried microspheres is consistent. Figure 4 The external diameter of the freeze-dried microspheres was measured by randomly selecting 3-4 microspheres from three vials using a vernier caliper. The specific results are shown in Table 8.

[0093] Table 8 Appearance measurement results

[0094]

[0095] 3.2 Accelerated stability assessment

[0096] The freeze-dried microspheres were subjected to accelerated tests at 37°C and 50°C. The 50°C acceleration was mainly performed because the temperature during sea transportation may exceed 37°C, so the accelerated temperatures were set at 37°C and 50°C. The test cycles were tested according to 0 / 3 / 7 / 10 / 14 / 18 / 21 / 24 / 28 / 31 / 35 / 38 / 42 days. The test results are shown in Table 9. It can be seen from the test results that within 35 days of 37°C acceleration, there is no significant difference in performance compared with that without acceleration, and there is no significant difference in performance compared with day 0; within 28 days of 50°C acceleration, there is no significant difference in performance compared with that without acceleration, and there is no significant difference in performance compared with day 0;

[0097] Table 9 Accelerated stability evaluation results

[0098]

[0099]

[0100] From the above experiments, it can be concluded that the freeze-dried protective agent formula, freeze-dried nucleic acid reaction reagent and freeze-drying method of the present invention have a good protective effect on PCR reaction reagents. Adding a simple protective agent combined with an optimal freezing method not only makes the freeze-dried reagent consistent with the 0-day result within 35 days, but also can reach 28 days at 50°C. The appearance is well formed, the yield is high, and the appearance and size of the freeze-dried microspheres are appropriate.

[0101] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0102] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0103] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.

Claims

1. A freeze-drying protective agent for freeze-drying protection of DNA / RAN reaction reagents, It is characterized in that The invention comprises 3-12 (w / v)% of trehalose, 2-8 (w / v)% of hydroxypropyl-β-cyclodextrin, 0.5-5 (w / v)% of dextran-40, 4-12 mg / mL of glycine, 0.1-0.7 (wt)% of antibacterial agent, and the rest is water.

2. The lyoprotectant according to claim 1, It is characterized in that The trehalose comprises 6-12 (w / v)%, 3-5 (w / v)% hydroxypropyl-β-cyclodextrin, 0.5-2 (w / v)% dextran-40, 7-10 mg / mL glycine, 0.1-0.4 (wt)% antibacterial agent, and the balance is water.

3. A freeze-dried nucleic acid reaction reagent, It is characterized in that include: PCR reaction reagents; The lyoprotectant according to claim 1 or 2.

4. The freeze-dried nucleic acid reaction reagent according to claim 3, It is characterized in that The PCR reaction reagents include a buffer, a surfactant, a glycerol-free enzyme, a primer and a probe; Wherein, the buffer solution is a buffer solution without glycerol, and the primers and probes are primers and probes purified by HPLC.

5. The freeze-dried nucleic acid reaction reagent according to claim 3, It is characterized in that The volume ratio of the lyophilized protective agent to the PCR reaction reagent is 1:

1.

6. A freeze-drying method for nucleic acid reaction reagents, It is characterized in that include: Mixing the lyophilized protective agent and the PCR reaction reagent to form a mixed solution; The lyoprotectant is the lyoprotectant according to claim 1 or 2; The mixed solution is added into a liquid nitrogen container to condense and form microspheres; The microspheres are transferred to a freeze dryer and freeze-dried according to a predetermined freeze-drying program to obtain finished freeze-dried reaction reagent microspheres.

7. The freeze-drying method of the nucleic acid reaction reagent according to claim 6, It is characterized in that The predetermined freeze-drying program includes: Pre-freezing stage: maintain the temperature at 4°C for 1.5-2 hours, then lower the temperature to -40 to -50°C and maintain for 1-3 hours; Sublimation drying stage: maintain vacuum degree of 8 to 15 Pa, first at -50 ° C for 8 hours; then adjust the temperature to -45 ° C for 4 hours; then adjust the temperature to -35 ° C for 6 hours; then adjust the temperature to -25 ° C for 4 hours; finally, adjust the temperature to -10 ° C for 4 hours; Analysis and drying stage: maintain a vacuum degree of 8 to 15 Pa, first at a temperature of 5 ° C for 4 hours; then adjust the temperature to 25 ° C for 6 hours; finally adjust the temperature to 35 ° C for 4 hours.